FILLMED® Testimonials and Reviews — What Practitioners Say

FILLMED® testimonials and reviews can offer insight into how medical professionals assess the company’s injectable treatments and skin-quality protocols. However, practitioner experience should be distinguished from clinical trial findings, which measure treatment outcomes under defined study conditions. Doctor Medica has gathered the published evidence and industry commentary on FILLMED® into a single overview of FILLMED® reviews and how FILLMED®’s protocol is being described.

This article will explore what the trial literature and trade commentary say about NCTF® 135 HA and the ART FILLER® range, how reviewers describe safety, how the brand is positioned against Juvéderm®, and which results come up most often. For practices looking to buy FILLMED® wholesale, distinguishing clinical evidence from practitioner opinion can support more informed product evaluations.

Key Takeaways

• The published evidence most often returns to NCTF® 135 HA, which the brand’s protocol presents as its biorevitalizing anchor.
• Published ART FILLER® studies provide information on correction outcomes and tolerability, but those results should not be presented as a consensus of practitioner reviews [2][3][4][5].
• Comparative studies reported non-inferiority for ART FILLER® Universal against Juvéderm® Ultra 3 and Fine Lines against Teoxane FIRST LINES PureSense. The subsequent 18-month extension evaluated the FILLMED®-treated areas without continuing the original head-to-head comparison [3].

About: Doctor Medica is your trusted supplier of top-quality dermal fillers, viscosupplements, and more for your medical practice. We offer genuine products from leading brands at the lowest prices in the market. If you’re looking to buy FILLMED® for your practice, contact Doctor Medica today.

What Are Practitioners Saying About FILLMED®?

Published practitioner feedback offers insight into how FILLMED® products are used in clinical practice, particularly NCTF® 135 HA and its role in combined aesthetic treatments. In a 2025 international survey involving 507 practitioners across 60 countries, 80.3% of respondents who answered the relevant question (298 of 371) reported using NCTF® 135 HA both independently and alongside other aesthetic procedures [6].

The survey also identified practical considerations affecting treatment decisions. Some practitioners cited limited experience, treatment costs, and uncertainty about additional benefits as reasons for not combining NCTF® 135 HA with other procedures [6]. Published practitioner commentary similarly discusses incorporating NCTF® into individualized treatment plans, although individual experiences cannot establish overall satisfaction with the FILLMED® portfolio [7].

These findings provide a perspective on clinical preferences and practical considerations rather than a universal rating of FILLMED® products. The clinical studies discussed elsewhere in this article offer separate evidence about treatment outcomes and tolerability [1][2][3][5]. Both the practitioner survey and manufacturer-supported clinical research should be interpreted with attention to study design, limitations, and funding sources.

What Do Clinicians Say About the FILLMED® Protocol and NCTF® 135 HA?

Practitioner discussions of NCTF® 135 HA often concern treatment planning, session scheduling, and its use alongside other aesthetic procedures. The survey and practitioner commentary discussed above provide insight into these clinical considerations [6][7].

Published studies separately document improvements in superficial wrinkles, radiance, and hydration [1]. However, these outcomes do not automatically substantiate broader claims about improved skin-cell turnover or reduced clogged pores.

SKIN PERFUSION may also be incorporated into broader FILLMED® treatment plans as complementary topical care, distinct from injectable NCTF® treatments.

How Do Practitioners Rate the FILLMED® ART FILLER® Range?

Practitioner experience with the FILLMED® ART FILLER® line includes observations about injection handling, treatment flexibility, and post-procedure responses. In a manufacturer-published account, one aesthetic practitioner described ART FILLER® Lips Soft favorably in terms of ease of injection and limited swelling [8]. However, this represents individual clinical experience rather than a representative assessment of the range.

Published research provides separate information about ART FILLER® outcomes and tolerability across different facial indications [3][4]. Clinics assessing practitioner feedback should consider those findings alongside the source, context, and limitations of individual reviews.

What Do Reviews Say About Safety and Side Effects?

Published ART FILLER® studies provide information about injection-related reactions and treatment tolerability. These findings help clinicians assess safety-related claims in reviews, although controlled study reporting is different from spontaneous practitioner or patient feedback.

In the ART FILLER® Lips trial, 28 of 100 participants reported adverse events associated with the product or injection procedure, including swelling, hematoma, pain, and palpable irregularities; the reported treatment-related events resolved within days or weeks [2]. A separate Universal study reported local reactions consistent with HA filler treatment, most of which resolved within 14 days [5].

How Should Practitioners Interpret FILLMED® and Juvéderm® Comparisons?

Comparative clinical research found ART FILLER® Universal non-inferior to Juvéderm® Ultra 3 for nasolabial fold correction. In the same research program, ART FILLER® Fine Lines was compared with Teoxane FIRST LINES PureSense for crow’s feet, rather than with a Juvéderm® product [3]. These findings are relevant when assessing comparative claims, but they do not establish overall practitioner preference for one filler brand over another.

During the open-label 18-month extension, exploratory analyses found that 98.3% of ART FILLER® Universal-treated nasolabial folds and 48.4% of ART FILLER® Fine Lines-treated crow’s-feet areas showed at least a one-point reduction from baseline in Lemperle wrinkle-severity scores [3]. Both figures are outcomes on the FILLMED®-treated sides only; they are not head-to-head retention comparisons against Juvéderm® or Teoxane at 18 months.

How Should Clinics Interpret Reported FILLMED® Results?

When evaluating FILLMED® testimonials, clinics should distinguish patient-reported satisfaction from investigator-rated improvement and objectively measured clinical outcomes. These measures provide different kinds of information and should not be treated as interchangeable.

For example, the ART FILLER® Lips study reported 18-month protocol-defined success rates of 91% for nasolabial folds and 33% for lips [2]. Subject-rated Global Aesthetic Improvement Scale findings were different: 71% and 30%, respectively, reported improvement at those sites [2].

Similarly, the NCTF® trial documented improvements in superficial wrinkles, radiance, and hydration [1], but those endpoints do not automatically substantiate broader claims about blemishes, clogged pores, or skin-cell turnover.

For practitioners, the most useful interpretation considers who reported the outcome, how it was measured, how long participants were followed, and whether the evidence came from a controlled trial or individual treatment experience.

Looking to buy FILLMED® products online? Get in touch with our customer service representatives at Doctor Medica for further guidance.

For licensed medical professionals only. This content is for informational purposes only and does not constitute medical advice.

Citations

[1] Fanian, Ferial et al. “A hyaluronic acid-based micro-filler improves superficial wrinkles and skin quality: a randomized prospective controlled multicenter study.” The Journal of dermatological treatment vol. 34,1 (2023): 2216323. doi:10.1080/09546634.2023.2216323

[2] Ehlinger-David, Agnès et al. “A prospective multicenter clinical trial evaluating the efficacy and safety of a hyaluronic acid-based filler with Tri-Hyal technology in the treatment of lips and the perioral area.” Journal of cosmetic dermatology vol. 22,2 (2023): 464-472. doi:10.1111/jocd.15169

[3] Trevidic, Patrick et al. “Objective 18-month Comparison of the Tolerability of 2 Dermal Fillers Formulated with Tri-Hyal Technology.” Plastic and reconstructive surgery. Global open vol. 8,12 e3274. 9 Dec. 2020, doi:10.1097/GOX.0000000000003274

[4] Cartier, Hugues et al. “Long-Term Performance and Safety of a Superficial HA Filler With Tri-Hyal Technology on Different Facial Zones: Forehead, Cheeks, Crow’s Feet, and Upper Lips.” Journal of cosmetic dermatology vol. 24,1 (2025): e16565. doi:10.1111/jocd.16565

[5] David, Michel et al. “Long-Term Efficacy and Tolerability of a Medium G’ HA Filler with Tri-Hyal Technology on the Rejuvenation of the Mobile Facial Zone.” Clinical, cosmetic and investigational dermatology vol. 16 1795-1805. 13 Jul. 2023, doi:10.2147/CCID.S395353

[6] Fanian, Ferial et al. “An International Survey on the Use of a Polyrevitalizing Solution With or Without Other Aesthetic Procedures in the Daily Practice of Aesthetic Physicians.” Journal of cosmetic dermatology vol. 24,2 (2025): e16623. doi:10.1111/jocd.16623

[7] “Unlocking Synergy.” Aesthetic Medicine, Nov.–Dec. 2024, mag.aestheticmed.co.uk/articles/269984?article=40-1.

[8] FILLMED. “FILLMED Newsletter: December 2019.” FILLMED, Dec. 2019, uk.fillmed.com/wp-content/uploads/2022/01/December-2019.pdf.